DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 18F-DOPA; 1H-Pyrazol; 2S,4R-(-)-ketoconazole; 2S,4R-(-)-ketoconazole, levoketoconazole; ATR-101; AZD4017; AZD4017 and prednisolone; Abiraterone; Abiraterone Acetate; Acetate; Acthrel; Bexarotene; CABERGOLINE; CABERGOLINE TEVA; CI-984; CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE; COR-003; CORT125134; Cabergoline; Calcium; Calcium carbonate; Carbonate; Corticotropin; Corticotropin-releasing hormone; Cushing's syndrome confirmation; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate; Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate; Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe); DDAVP; DOSTINEX; Device: IPC; Device: continuous glucose monitoring; Dexamethasone; Diagnostic Test: 24-hour Urine test; Diagnostic Test: Blood test; Diagnostic Test: CT scan; Diagnostic Test: Dexamethasone test; Diagnostic Test: MRI; Diagnostic Test: Saliva swab; Dostinex; Dotatate; Eplerenone; Gefitinib; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; Glucocorticoids; Glucophage (metformin); Glucose; HRA052015; HRA052015 (mifepristone); Hydrocortisone; Hypro; Insulin; KETOCONAZOLE; Ketoconazole; L0006CP03A; LA; LCI699; LCI699, 1 mg; LCI699, 10 mg; LCI699, 20 mg; LCI699, 5 mg; LMWH/Rivaroxaban; Lapatinib; Levoketoconazole; Levoketozonazole; Liqourice; Liraglutide; METYRAPONE; MIFEPRISTONE; Matyrapone; Metformin; Methionine; Metopirone; Metopirone 250 mg capsules; Metopirone 250 mg capsules/Cormeto; Metyrapone; Mifedren; Mifepristone; NIZORAL; Nevanimibe; Nevanimibe hydrochloride; Nizoral; OROCAL; OSILODROSTAT; OSTEOPOR; Octreotide; Osilodrostat; Osilodrostat 10mg; Osilodrostat 1mg; Osilodrostat 20mg; Osilodrostat 5mg; Ossein hydroxyapatite; Other: Control; Other: Hydrocortisone; Other: Obese; Other: [11C]-Methionine PET/MRI; Ovine Corticotropin-Releasing Hormone (oCRH); PASIREOTIDE; PASIREOTIDE DIASPARTATE; PASIREOTIDE PAMOATE; Pasireotida; Pasireotida 300; Pasireotida 600; Pasireotida 900; Pasireotide; Pasireotide 0.3mg; Pasireotide 0.6 MG/ML; Pasireotide 0.6mg; Pasireotide 0.9 mg; Pasireotide 20mg; Pasireotide 40mg; Pasireotide 60mg; Pasireotide LAR; Pasireotide pamoate; Pasireotide s.c.; Pasireotide sub-cutaneous; Pasireotide with or without cabergoline; Pasireotode; Pentetreotide; Phe; Prednisolone; Procedure: Hypercortisolism; Procedure: Lateral transperitoneal LA; Procedure: Posterior RA; R-roscovitine; RVG 08938; RVG 15375; RVG 18236; Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Relacorilant; Rivaroxaban; Rosiglitazone; Rosiglitazone maleate; SIGNIFOR; SOM230; SOM230 300µg; SOM230 600µg; SOM230 900µg; SOM230 LAR; SOM230 LAR 10 mg; SOM230 LAR 30 mg; SOM230 LAR, 20 mg; SOM230 s.c.; SOM230, 300micrograms; SOM230, 600 micrograms; SOM230, 900 micrograms; SOM230B; SOMATROPIN; Seliciclib; Signifor; Sitagliptin; Somatropin; Tadalafil; Tretinoin; Trp; Tyr; Valsartan; Vorinostat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01925092 (ClinicalTrials.gov)	August 2013	8/8/2013	Mifepristone in Children With Refractory Cushing's Disease	An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease	Cushing's Disease	Drug: mifepristone	Corcept Therapeutics	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Withdrawn	6 Years	17 Years	Both	0	Phase 3	United States
2	NCT01371565 (ClinicalTrials.gov)	November 2010	7/6/2011	Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome	Cushing's Disease;Cushing's Syndrome	Drug: Mifepristone	Corcept Therapeutics	NULL	Completed	18 Years	N/A	All	4	Phase 3	United States
3	NCT00936741 (ClinicalTrials.gov)	July 2009	9/7/2009	An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome	An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome	Cushing's Syndrome	Drug: mifepristone	Corcept Therapeutics	NULL	Completed	18 Years	N/A	All	30	Phase 3	United States
4	NCT00721201 (ClinicalTrials.gov)	November 2008	21/7/2008	Glucocorticoid Receptor Antagonism in Subclinical Cushings	A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings	Subclinical Cushing's	Drug: Mifepristone	Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Completed	18 Years	N/A	Both	6	Phase 1;Phase 2	United Kingdom
5	NCT00569582 (ClinicalTrials.gov)	December 2007	5/12/2007	A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome	An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome	Cushing's Syndrome	Drug: mifepristone	Corcept Therapeutics	NULL	Completed	18 Years	N/A	All	50	Phase 3	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00422201 (ClinicalTrials.gov)	May 15, 2007	12/1/2007	Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion	Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion	Cushing's Syndrome	Drug: Mifepristone	HRA Pharma	NULL	Terminated	18 Years	85 Years	All	18	Phase 2	United States;France;Germany;Italy;Netherlands;United Kingdom
7	EUCTR2006-004679-36-DE (EUCTR)	05/04/2007	09/10/2006	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. MedDRA version: 14.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.0;Classification code 10014146;Term: Ectopic ACTH syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Code: HRA052015 INN or Proposed INN: mifepristone Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	35		France;United States;Netherlands;Germany;Italy
8	EUCTR2006-004679-36-NL (EUCTR)	22/03/2007	31/01/2007	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome	Product Code: HRA052015 INN or Proposed INN: mifepristone Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	22		Germany;Netherlands;France;Italy
9	EUCTR2006-004679-36-IT (EUCTR)	15/01/2007	30/01/2007	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS	Cushing s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone ACTH Secretion MedDRA version: 9.1;Level: LLT;Classification code 10014146;Term: Ectopic ACTH syndrome	Product Name: Mifepristone Product Code: HRA052015	LABORATOIRE HRA PHARMA	NULL	Not Recruiting			Female: yes Male: yes	22		Germany;Netherlands;France;Italy
10	EUCTR2006-004679-36-FR (EUCTR)	13/12/2006	29/09/2006	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS	Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome	Product Code: HRA052015 INN or Proposed INN: mifepristone Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	22		France;Netherlands;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01925092
(ClinicalTrials.gov)

August 2013

8/8/2013

Mifepristone in Children With Refractory Cushing's Disease

An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease

Cushing's Disease

Drug: mifepristone

Corcept Therapeutics

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Withdrawn

6 Years

17 Years

Both

Phase 3

United States

NCT01371565
(ClinicalTrials.gov)

November 2010

7/6/2011

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Cushing's Disease;Cushing's Syndrome

Drug: Mifepristone

Corcept Therapeutics

NULL

Completed

18 Years

N/A

All

Phase 3

United States

NCT00936741
(ClinicalTrials.gov)

July 2009

9/7/2009

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Cushing's Syndrome

Drug: mifepristone

Corcept Therapeutics

NULL

Completed

18 Years

N/A

All

Phase 3

United States

NCT00721201
(ClinicalTrials.gov)

November 2008

21/7/2008

Glucocorticoid Receptor Antagonism in Subclinical Cushings

A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings

Subclinical Cushing's

Drug: Mifepristone

Sheffield Teaching Hospitals NHS Foundation Trust

NULL

Completed

18 Years

N/A

Both

Phase 1;Phase 2

United Kingdom

NCT00569582
(ClinicalTrials.gov)

December 2007

5/12/2007

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Cushing's Syndrome

Drug: mifepristone

Corcept Therapeutics

NULL

Completed

18 Years

N/A

All

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00422201
(ClinicalTrials.gov)

May 15, 2007

12/1/2007

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Cushing's Syndrome

Drug: Mifepristone

HRA Pharma

NULL

Terminated

18 Years

85 Years

All

Phase 2

United States;France;Germany;Italy;Netherlands;United Kingdom

EUCTR2006-004679-36-DE
(EUCTR)

05/04/2007

09/10/2006

Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS

Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 14.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Classification code 10014146;Term: Ectopic ACTH syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Netherlands;Germany;Italy

EUCTR2006-004679-36-NL
(EUCTR)

22/03/2007

31/01/2007

Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome

Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Germany;Netherlands;France;Italy

EUCTR2006-004679-36-IT
(EUCTR)

15/01/2007

30/01/2007

Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS

Cushing s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone ACTH Secretion
MedDRA version: 9.1;Level: LLT;Classification code 10014146;Term: Ectopic ACTH syndrome

Product Name: Mifepristone
Product Code: HRA052015

LABORATOIRE HRA PHARMA

NULL

Not Recruiting

Female: yes
Male: yes

Germany;Netherlands;France;Italy

EUCTR2006-004679-36-FR
(EUCTR)

13/12/2006

29/09/2006

Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome

Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

France;Netherlands;Germany;Italy